Amy Prangnell1,2, Christopher Fairgrieve1,3, Ekaterina Nosova1, Kora DeBeck1,4, M-J Milloy1,3, Kanna Hayashi1,5. 1. a British Columbia Centre on Substance Use , British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital , Vancouver , British Columbia , Canada. 2. b School of Population and Public Health , University of British Columbia , Vancouver , British Columbia , Canada. 3. c Department of Medicine , University of British Columbia, St. Paul's Hospital , Vancouver , British Columbia , Canada. 4. d School of Public Policy , Simon Fraser University , Vancouver , British Columbia , Canada. 5. e Faculty of Health Sciences , Simon Fraser University , Burnaby , British Columbia , Canada.
Abstract
BACKGROUND: In North America, rates of overdoses are increasing largely due to the adulteration of illicit drugs by illicit synthetic opioids. OBJECTIVES: We sought to examine the prevalence and correlates of self-reported exposure to adulterated drugs among people who experienced a non-fatal opioid overdose. METHODS: Data were derived from three prospective cohort studies of people who use drugs in Vancouver, Canada between June and November 2016. Multivariable logistic regression analyses were used to examine the prevalence and correlates of self-reported exposure to adulterated drugs. RESULTS: Among 117 participants who reported symptoms consistent with a non-fatal opioid overdose, 78 (66.7%) reported believing the drug was adulterated during their last overdose. Of those, 42 (53.8%) had not perceived adulteration prior to overdose. In the multivariable analysis, engagement in opioid agonist therapy (Adjusted Odds Ratio [AOR] = 2.79, 95% Confidence Interval [CI]: 1.10, 7.45) was independently associated with having not perceived adulteration prior to overdose. Daily heroin use (AOR = 5.28; 95% CI: 1.92, 15.97) and reporting supervised injection site staff were present at most recent overdose (AOR = 6.16; 95% CI: 1.25, 47.27) were independently associated with having perceived adulteration prior to overdose. Conclusions/Importance: We found a high prevalence of believing adulterated drugs were present for the most recent overdose. Further, the high prevalence of unperceived adulteration prior to overdose supports the need to lower the risk of overdose by providing individuals with options to consume drugs in a safer manner, including supervised consumption sites.
BACKGROUND: In North America, rates of overdoses are increasing largely due to the adulteration of illicit drugs by illicit synthetic opioids. OBJECTIVES: We sought to examine the prevalence and correlates of self-reported exposure to adulterated drugs among people who experienced a non-fatal opioid overdose. METHODS: Data were derived from three prospective cohort studies of people who use drugs in Vancouver, Canada between June and November 2016. Multivariable logistic regression analyses were used to examine the prevalence and correlates of self-reported exposure to adulterated drugs. RESULTS: Among 117 participants who reported symptoms consistent with a non-fatal opioid overdose, 78 (66.7%) reported believing the drug was adulterated during their last overdose. Of those, 42 (53.8%) had not perceived adulteration prior to overdose. In the multivariable analysis, engagement in opioid agonist therapy (Adjusted Odds Ratio [AOR] = 2.79, 95% Confidence Interval [CI]: 1.10, 7.45) was independently associated with having not perceived adulteration prior to overdose. Daily heroin use (AOR = 5.28; 95% CI: 1.92, 15.97) and reporting supervised injection site staff were present at most recent overdose (AOR = 6.16; 95% CI: 1.25, 47.27) were independently associated with having perceived adulteration prior to overdose. Conclusions/Importance: We found a high prevalence of believing adulterated drugs were present for the most recent overdose. Further, the high prevalence of unperceived adulteration prior to overdose supports the need to lower the risk of overdose by providing individuals with options to consume drugs in a safer manner, including supervised consumption sites.
Authors: Alexandria Macmadu; Jennifer J Carroll; Scott E Hadland; Traci C Green; Brandon D L Marshall Journal: Addict Behav Date: 2017-01-06 Impact factor: 3.913
Authors: Melissa C Mercado; Steven A Sumner; M Bridget Spelke; Michele K Bohm; David E Sugerman; Christina Stanley Journal: Pain Med Date: 2018-03-01 Impact factor: 3.750
Authors: Mark W Tyndall; Sue Currie; Patricia Spittal; Kathy Li; Evan Wood; Michael V O'Shaughnessy; Martin T Schechter Journal: AIDS Date: 2003-04-11 Impact factor: 4.177
Authors: Donna A Volpe; Grainne A McMahon Tobin; R Daniel Mellon; Aspandiar G Katki; Robert J Parker; Thomas Colatsky; Timothy J Kropp; S Leigh Verbois Journal: Regul Toxicol Pharmacol Date: 2011-01-06 Impact factor: 3.271
Authors: Nicholas J Somerville; Julie O'Donnell; R Matthew Gladden; Jon E Zibbell; Traci C Green; Morgan Younkin; Sarah Ruiz; Hermik Babakhanlou-Chase; Miranda Chan; Barry P Callis; Janet Kuramoto-Crawford; Henry M Nields; Alexander Y Walley Journal: MMWR Morb Mortal Wkly Rep Date: 2017-04-14 Impact factor: 17.586